Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Swedish Orphan Biovitrum clinical trials
Also known as Sobi.
The registry lists 135 studies whose lead sponsor is Swedish Orphan Biovitrum or one of 2 companies grouped under it. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Keep track of what changes. Save the Swedish Orphan Biovitrum studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Swedish Orphan Biovitrum.
- Swedish Orphan Biovitrum80 studiesSame company
Something wrong?
- CTI BioPharma38 studies →Acquired — became part of Swedish Orphan Biovitrum, Jun 24, 2023 · source ↗
Something wrong?
- Arthrosi Therapeutics10 studies →Acquired — became part of Swedish Orphan Biovitrum, Feb 9, 2026 · source ↗
Something wrong?
- Sobi, Inc.7 studiesSame company
Something wrong?
Focus areas
Conditions Swedish Orphan Biovitrum leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 135. Browse all 135 →
- Pacritinib Effectiveness in Real-world SettingsRecruitingNCT07774455
- A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)RecruitingNCT06782373Phase 2
- Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country StudyRecruitingNCT07746895Phase 4
- A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard TreatmentNot yet recruitingNCT07786922Phase 2/3
- Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog AlfaActive, not recruitingNCT06716814Phase 3
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)CompletedNCT06439602Phase 3
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Assessment of Macrophage Activation syndromE in STill's DiseaseCompletedNCT06405152
- Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog AlfaActive, not recruitingNCT06940830Phase 4
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)CompletedNCT06846515Phase 3
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint HealthCompletedNCT04293523
- A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)Active, not recruitingNCT05776472
- A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese PatientsCompletedNCT05744063Phase 4
- Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLECompletedNCT05001737Phase 3
- An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)WithdrawnNCT07706868Phase 4
- A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaCompletedNCT05817812Phase 3
- A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMFWithdrawnNCT06666335Phase 4
- Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ACompletedNCT06579144Phase 1
- Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 MonthsCompletedNCT04516967Phase 3
Sponsor listed in the registry: Sobi, Inc.
- Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITPCompletedNCT05369208Phase 3
Sponsor listed in the registry: Sobi, Inc.
- Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed PatientsActive, not recruitingNCT07116746Phase 2
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia MyelofibrosisActive, not recruitingNCT03165734Phase 3
- A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa ProphylaxisActive, not recruitingNCT06752850Phase 4
- A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 PatientsWithdrawnNCT06227429
- A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy IICompletedNCT04596540Phase 3
- Assessment of Macrophage Activation syndromE in STill's Disease in ItalyCompletedNCT06992505
- A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell TransplantationCompletedNCT05148299Phase 2
- A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)CompletedNCT05096403Phase 3
- An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia BCompletedNCT03901755
- A Study of SEL-212 in Patients With Gout Refractory to Conventional TherapyCompletedNCT04513366Phase 3
- An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITPCompletedNCT04943042
- A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)Active, not recruitingNCT05814159Phase 3
- Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous GoutCompletedNCT05253833Phase 2
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or RomiplostimCompletedNCT04638829Phase 4
Sponsor listed in the registry: Sobi, Inc.
- An 18-month Low-interventional Study to Assess Joint Health in Haemophilia A and B Patients on Prophylaxis With Efmoroctocog Alfa or Eftrenonacog AlfaTerminatedNCT05856266Phase 4
- Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a ProcedureTerminatedNCT03554759
Sponsor listed in the registry: Sobi, Inc.
- Study to Evaluate the Safety, Tolerability, and PK of PacritinibCompletedNCT05552183Phase 1
Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum
- Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male SubjectsCompletedNCT05657613Phase 1
Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum
- A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or BCompletedNCT03055611
- Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor ProductsCompletedNCT02976753
- Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic LymphohistiocytosisCompletedNCT03259230
- Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)CompletedNCT03932344
- Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)CompletedNCT04731701
- A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in FranceCompletedNCT03655340
- Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic LymphohistiocytosisCompletedNCT06047210
- Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI TherapiesCompletedNCT03103542Phase 4
- rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia ACompletedNCT03951103
- Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical CareCompletedNCT02320084
- Impact on French Physician's Haemophilia Treatment Management Decision Based on Systematic Joint ExaminationCompletedNCT04133883Not applicable
- PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without CancerTerminatedNCT04404361Phase 2
Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum
- A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against DoxorubicinCompletedNCT00268853Phase 2
Sponsor listed in the registry: CTI BioPharma · First submitted before CTI BioPharma became part of Swedish Orphan Biovitrum